Condition: New Onset Generalized Myasthenia Gravis (gMG) · Sponsor: argenx
The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.
This description comes directly from the study's public registry record.
Sabine Coppieters, MD · 857-350-4834 · clinicaltrials@argenx.com
Always discuss trial participation with your own doctor first.
| University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI) | La Jolla, California, United States | Recruiting |
| Samir Macwan, M.D., Inc. (S corporation) | Rancho Mirage, California, United States | Recruiting |
| EZR Research | Boca Raton, Florida, United States | Recruiting |
| University of Florida Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Visionary Investigators Network | Miami, Florida, United States | Recruiting |
| University of California Irvine | Orange, Florida, United States | Recruiting |
| Medsol Clinical Research Center Inc | Port Charlotte, Florida, United States | Recruiting |
| Baycare Medical Group | St. Petersburg, Florida, United States | Recruiting |
| Emory Brain Health Center | Atlanta, Georgia, United States | Recruiting |
| The Queen's Medical Center - West Oahu | Honolulu, Hawaii, United States | Recruiting |
| Hawaii Pacific Neuroscience | Honolulu, Hawaii, United States | Recruiting |
| HSHS Medical Group | O'Fallon, Illinois, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06909214